As our use of new MS drugs progresses, real-world evidence starts becoming available that usefully complements trials-derived knowledge. Beyond informing us on how to best move from one drug to another one, it can also refine our understanding of the longer-term consequences of the treatment choices we pose today and help us best tailoring drug choices to individual patient needs. To discuss these key elements, we have here a panel of experts who will complement mechanistic and trial considerations with their own extensive experiences, in order to share useable and practical advices and tips.
Dermatology ...
Geaccrediteerd voor artsen (N° 25019731 - 1.5 punten)
Endocrinology and metabolic diseases
Geaccrediteerd voor artsen (N° 24010541 - 1 punt)
Healthcare
Geaccrediteerd voor artsen (N° 24018766 - 1 punt)
Rhumatology & Orthopedy
Cardiology
Geaccrediteerd voor artsen (N° 25016629 - 1 punt)
Oncology
Geaccrediteerd voor artsen (N° 25016902 - 1 punt)
Geaccrediteerd voor artsen in ethiek en economie (1 punt)
Geaccrediteerd voor artsen - 25016629 - 1 CP
Geaccrediteerde lectuur voor artsen (25016902 - 1 CP)
